Literature DB >> 10806607

Effect of metoprolol and verapamil administered separately and concurrently after single doses on liver blood flow and drug disposition.

L A Bauer1, J R Horn, M S Maxon, T R Easterling, D D Shen, D E Strandness.   

Abstract

Nine healthy males participated in a double-blind, placebo-controlled, randomized, crossover study to determine the effects of verapamil and metoprolol administered alone and concurrently on blood flow through the hepatic artery and portal and hepatic veins and to detect a possible drug interaction between the two agents. Single oral doses of placebo/placebo, metoprolol (50 mg)/placebo, verapamil (80 mg)/placebo, or verapamil/metoprolol were separated by at least 14 days. Liver blood flow through individual hepatic vessels was measured up to 8 hours after dosage administration using a duplex Doppler ultrasound technique. Cardiac output, heart rate, blood pressure, stroke volume, and total peripheral resistance were measured for 3 hours after drug doses were given. In 5 subjects, pharmacokinetic parameters for total drug as well as S- and R-enantiomers were also measured. Verapamil given alone caused a rapid and intense increase in liver blood flow (hepatic artery = 50%, portal vein = 42%, hepatic vein = 55%) 0.75 to 1 hour after administration because of a decrease in total peripheral resistance and an increase in heart rate, stroke volume, and cardiac output. Metoprolol given alone caused a slow but prolonged decrease in liver blood flow (maximum decrease: hepatic artery = -54%, portal vein = -21%, hepatic vein = -27%) 4 hours after administration because of a decrease in heart rate and cardiac output. When the two agents were given together, a composite of the changes noted after separate administration was noted: a brief peak increase in liver blood flow at 0.33 to 1 hour followed by a slow, prolonged decrease that reached its maximum decline 4 to 5 hours postdose. During the combined phase, metoprolol and its enantiomers had an increased AUC and Cmax, while verapamil and its enantiomers had an increased AUC and t1/2. These pharmacokinetic changes were consistent with the magnitude and time course of liver blood flow changes through the hepatic artery and portal or hepatic veins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10806607     DOI: 10.1177/00912700022009152

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  Validation of the hepatic blood flow rate model for verapamil first-pass metabolism.

Authors:  Jovan Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jan-Mar       Impact factor: 2.441

3.  Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.

Authors:  Markus Grube; Sabine Ameling; Michel Noutsias; Kathleen Köck; Ivonne Triebel; Karina Bonitz; Konrad Meissner; Gabriele Jedlitschky; Lars R Herda; Markus Reinthaler; Maria Rohde; Wolfgang Hoffmann; Uwe Kühl; Heinz-Peter Schultheiss; Uwe Völker; Stephan B Felix; Karin Klingel; Reinhard Kandolf; Heyo K Kroemer
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

4.  Application of one-compartmental bio-metric blood loss calculations with transfused blood volume taken into account after aneurysmectomy.

Authors:  Nataša Božičković; Jovan Popović; Radmila Kolak; Kosta Popović; Dušica Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-15       Impact factor: 2.441

5.  Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m).

Authors:  Michael Streit; Christoph Göggelmann; Christoph Dehnert; Jürgen Burhenne; Klaus-Dieter Riedel; Elmar Menold; Gerd Mikus; Peter Bärtsch; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2005-02-04       Impact factor: 2.953

6.  Influence of pregnancy on one-compartmental bio-metric blood loss calculations after cesarean section and gynaecological surgery.

Authors:  Jovan Popović; Zorica Grujić
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jan-Mar       Impact factor: 2.441

7.  Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site.

Authors:  Helen Musther; Katherine L Gill; Manoranjenni Chetty; Amin Rostami-Hodjegan; Malcolm Rowland; Masoud Jamei
Journal:  AAPS J       Date:  2015-06-23       Impact factor: 4.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.